Patents/Assignees

Janssen Pharmaceutica NV

136 patents in portfolio

US12201690utility2025
Formulations/compositions Comprising Ibrutinib
0 cites
US12202831utility2025
Small Molecule Inhibitors of the JAK Family of Kinases
0 cites
US12188938utility2025
Anti-vista Antibodies and Fragments
0 cites
US12180221utility2024
Compounds and Uses Thereof
0 cites
US12172997utility2024
Substituted Pyrazolo-pyridine Amides and Their Use as Glun2b Receptor Modulators
0 cites
US12173007utility2024
Imidazopyridazine IL-17 Inhibitor Compounds
0 cites
US12145934utility2024
Azabenzimidazoles and Their Use as AMPA Receptor Modulators
0 cites
US12145961utility2024
Spirobicyclic Analogues
0 cites
US12139485utility2024
Azabenzimidazoles and Their Use as AMPA Receptor Modulators
0 cites
US12133851utility2024
Treatment of Cholangiocarcinoma
0 cites
US12134636utility2024
Immunoglobulins and Uses Thereof
0 cites
US12098146utility2024
Compounds and Uses Thereof
0 cites
US12084462utility2024
Spiro Bicyclic Inhibitors of Menin-mll Interaction
0 cites
US12077521utility2024
Pyrazole Derivatives as MALT1 Inhibitors
0 cites
US12077757utility2024
Modified Oligonucleotides and Methods of Use
0 cites
US12073742utility2024
System and Method for Assessing Cognitive and Mood States of a Real World User as a Function of Virtual World Activity
0 cites
US12065446utility2024
Inhibitors of Bruton's Tyrosine Kinase and Method of Their Use
0 cites
US12053474utility2024
Dosing Regimens Associated with Extended Release Paliperidone Injectable Formulations
0 cites
US12048696utility2024
Combinations Comprising Positive Allosteric Modulators or Orthosteric Agonists of Metabotropic Glutamatergic Receptor Subtype 2 and Their Use
0 cites
US12037644utility2024
Use of FGFR Mutant Gene Panels in Identifying Cancer Patients That Will Be Responsive to Treatment with an FGFR Inhibitor
0 cites

← PreviousPage 3 of 7Next →